Also found in: Acronyms, Encyclopedia, Wikipedia.

os·te·o·pro·teg·er·in (OPG),

Polypeptide suppressing osseous mineral turnover deficient in juvenile onset Paget disease.
[osteo- + L. protego, protegere, to protect, + -in]
Farlex Partner Medical Dictionary © Farlex 2012


A secreted protein that inhibits osteoclast differentiation.
[osteo- + L. protego, protegere, to protect, + -in]
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

osteoprotegerin (OPG)

A secreted protein which inhibits osteoclast differentiation. The cytokine TRANCE binds to osteoprotegerin. Recombinant osteoprotegerin has been used successfully to treat juvenile PAGET'S DISEASE.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Lambert et al., "Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients," Clinical and Experimental Immunology, vol.
Moon, "Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor [kappa]B, osteoprotegerin, and receptor activator of nuclear factor [kappa]B ligand," Arthritis & Rheumatism, vol.
Native human osteoprotegerin amino acid sequence, N-terminal signaling peptide (gray) 1 mnkllccalv fldisikwtt qetfppkylh ydeetshqll cdkcppgtyl kqhctakwkt 61 vcapcpdhyy tdswhtsdec lycspvckel qyvkqecnrt hnrvceckeg ryleiefclk 121 hrscppgfgv vqagtpernt vckrcpdgff snetsskapc rkhtncsvfg llltqkgnat 181 hdnicsgnse stqkcgidvt lceeaffrfa vptkftpnwl svlvdnlpgt kvnaesveri 241 krqhssqeqt fqllklwkhq nkdqdivkki iqdidlcens vqrhighanl tfeqlrslme 301 slpgkkvgae diektikack psdqilklls lwrikngdqd tlkglmhalk hsktyhfpkt 361 vtqslkktir flhsftmykl yqklflemig nqvqsvkisc 1 Purified hOPG functional assessment via OPG--RANKL complex formation
Ng et al., "Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model," Journal of Pediatric Surgery, vol.
Kiyoshima et al., "In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue," Journal of Periodontal Research, vol.
Wang, "The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat," European Journal of Pharmacology, vol.
Karan, "Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis," Stroke, vol.
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals.
Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).
RANKL also binds to osteoprotegerin (OPG), a decoy receptor, which reduces resorption.
RANK-L is counteracted by naturally occurring osteoprotegerin (OPG), another TNF family member that binds and subsequently prevents activation of its single cognate receptor, RANK, thus, making osteoclastic activity dependent on the balance between both RANK-L as well as OPG [39].